Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of “Buy” by Analysts
Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. […]
Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. […]
